title: Polycystic ovarian disease.
abstract: Sex hormone binding globulin (SHBG) capacity was reduced in 9 of 31 patients with polycystic ovarian (PCO) disease and the mean level in PCO patients was significantly less (p less than 0.001) than normal. Serum testosterone levels were elevated in 21 of 32 PCO patients and the mean level was significantly elevated (p less than 0.001). Serum androstenedione values were raised in 17 of 31 patients and the mean value was also significantly raised (p less than 0.001). Serum dehydroepiandrosterone sulphate (DHAS) concentrations were elevated in only 2 of 14 patients. Urinary 17-oxo and 17-oxogenic steroids were normal in all patients studied. Basal follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels were normal but LH release following injection of luteinizing hormone-releasing hormone (LH-RH) was enhanced. A highly significant negative correlation (r=--0.449; p less than 0.01) was found between the logarithm of testosterone and the logarithm of LH levels. Serum prolactin concentrations were elevated in 4 of 21 PCO patients. Thyroid-stimulating hormone (TSH) values were normal. Eighteen of 20 patients ovulated following treatment with clomiphene and nine became pregnant. Five of 12 of patients treated with oestrogen/progesterone preparations noticed an improvement in their hirsutism. It is suggested that the normal cyclical release of LH is inhibited in PCO disease by a negative feedback by androgens to the hypothalamus or the pituitary, and that wedge resection should be reserved for patients in whom other forms of treatment have failed.
mesh_terms: D000735:Androstenedione / Q000097:blood; D002996:Clomiphene / Q000627:therapeutic use; D003687:Dehydroepiandrosterone / Q000097:blood; D003864:Depression, Chemical; D003907:Dexamethasone / Q000494:pharmacology; D004958:Estradiol / Q000627:therapeutic use; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D007987:Gonadotropin-Releasing Hormone / Q000494:pharmacology; D006628:Hirsutism / Q000188:drug therapy; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008593:Menopause; D010053:Ovary / Q000601:surgery; D010060:Ovulation / Q000187:drug effects; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000628:therapy; D011247:Pregnancy; D011374:Progesterone / Q000627:therapeutic use; D011388:Prolactin / Q000097:blood; D011485:Protein Binding; D012712:Serum Globulins / Q000032:analysis; D013739:Testosterone / Q000097:blood; D013972:Thyrotropin / Q000097:blood
chemical_list: D012712:Serum Globulins; D002996:Clomiphene; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone; D000735:Androstenedione; D003687:Dehydroepiandrosterone; D011374:Progesterone; D004958:Estradiol; D003907:Dexamethasone; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D013972:Thyrotropin